Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sona NanotechSNANF -22.65%26 Days Payable is 0.00 as of Apr. 2026. GuruFocus rates SNANF with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 703 Biotechnology companies, Sona Nanotech ranks worse than 142247.37% on this metric.
The historical rank and industry rank for Sona Nanotech's Days Payable or its related term are showing as below:
SNANF's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 112.39 * Ranked among companies with meaningful Days Payable only.
Sona Nanotech's Days Payable
stayed the same
from Apr. 2025 (0.00) to Apr. 2026 (0.00).
stayed the same
The historical data trend for Sona Nanotech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SNANF vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Sona Nanotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sona Nanotech Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sona Nanotech's Days Payable distribution charts can be found below:
* The bar in red indicates where Sona Nanotech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sona Nanotech's Days Payable for the fiscal year that ended in Oct. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sona Nanotech (SNANF) has a Days Payable of 0.00 as of Apr. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sona Nanotech and its competitors. According to the industry distribution chart, Sona Nanotech ranks #999999 out of 703 companies in the Biotechnology industry.
Is Sona Nanotech's Days Payable too high?
Sona Nanotech's current Days Payable is 0.00. Based on the distribution chart, Sona Nanotech ranks #999999 out of 703 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sona Nanotech has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Sona Nanotech's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sona Nanotech ranks #999999 out of 703 companies for Days Payable. This places Sona Nanotech in the lower half of its industry. The industry median Days Payable is 112.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.39, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sona Nanotech and its competitors. For the Biotechnology industry, the median Days Payable is 112.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sona Nanotech's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sona Nanotech stock overvalued right now?
Sona Nanotech (SNANF) has a current Days Payable of 0.00. The current Days Payable is 0.00. Sona Nanotech's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sona Nanotech (SNANF), the current Days Payable is 0.00 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sona Nanotech Inc is involved in the nanotechnology life sciences industry. It has developed two proprietary methods for the manufacture of rod-shaped gold nanoparticles and is engaged in the research and development of its proprietary technology for use in biomedical applications and multiplex diagnostic testing platforms. The company is using its gold nano rods manufacturing technology to develop new products and methods for cancer treatment, including a Targeted Hyperthermia Therapy (THT). Additionally, it has filed patent applications in the U.S. regarding a gold nanorod conjugation concept for targeted drug delivery, combination therapies for treating cancer, and for an endoscope with an optical fibre and thermal sensor for photothermal therapy.
26GF Score
Get the complete analysis for SNANF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNANF has been successfully added to your 
